Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 11/09/20 at 10:01am

The top 10 news stories this week largely cover COVID-19 vaccines, as hundreds of thousands of people in China have been inoculated with two experimental vaccines on an emergency use scheme, while Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical trials being paused after a participant became ill.

In broader pharmaceutical news, Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million, while Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million.

1. Up to 60,000 in the UK may have suffered from “long COVID” new data suggests

60,000 people across Britain may have been suffering from prolonged symptoms of coronavirus months after contracting the virus.

2. Gatherings of over six people to be banned in England from Monday

England is set to increase lockdown restrictions across the country after a surge in coronavirus cases.

3. Chinese drug firm says thousands have been vaccinated for COVID-19 on an emergency use scheme

Hundreds of thousands of people in China have been inoculated with two experimental vaccines on an emergency use scheme, according to a state-owned vaccine developer.

4. Takeda to sell another non-core portfolio for $260 million to Cheplapharm

Takeda has revealed it has agreed to divest its non-core portfolio of prescription therapies to Cheplapharm in exchange for an upfront payment of $562 million.

5. AstraZeneca slams brakes on COVID-19 vaccine trial over unexplained participant illness

Global trials for AstraZeneca’s much-hyped COVID-19 vaccine, currently in development in partnership with the University of Oxford, have been halted after an unexplained illness was identified in one of the participants.

6. Mylan reaches agreement with Aspen for their European thrombosis business

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s thrombosis business for €641.9 million.

7. Roche to start new trials of Ocrevus to defend multiple sclerosis franchise

Roche is to begin expanding trials of Ocrevus in multiple sclerosis (MS) patients to defend its MS franchise from its rivals.

8. AstraZeneca Chief Executive says vaccine is still possible this year

Pascal Soriot, Chief Executive of AstraZeneca, said that the company’s vaccine could still be available this year, despite the clinical trials being paused after a participant became ill.

9. Genetech scores sixth FDA approval in lung cancer with Gavreto

Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), it has emerged.

10. FDA approves GlaxoSmithKline’s Trelegy for treating asthma

The FDA has approved a new indication of Trelegy Ellipta for the treatment of asthma and patients with chronic obstructive pulmonary disease.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches